Oritavancin, a single-dose, complete regimen, for the treatment of acute bacterial skin and skin structure infections

References

• Amin AN, Cerceo EA, Deitelzweig SB, et al. Hospitalist perspective on treatment of skin and soft tissue infections. Mayo Clin Proc 2014;89(10):1436-51
   PubMed Web of Science ®Google Scholar
• Pallin DJ, Espinola JA, Leung DY, et al. Epidemiology of dermatitis and skin infections in United States physicians’ offices, 1993-2005. Clin Infect Dis 2009;49(6):901-7
   PubMed Web of Science ®Google Scholar
• Pallin DJ, Egan DJ, Pelletier AJ, et al. Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community associated methicillin-resistant Staphyloccocus aureus. Ann Emerg Med 2008;51(3):291-8
   PubMed Web of Science ®Google Scholar
• Edelsberg J, Taneja C, Zervos M, et al. Trends in US hospital admissions for skin and soft tissue infections. Emerg Infect Dis 2009;15(9):1516-18
   PubMed Web of Science ®Google Scholar
• Ki V, Rotstein C. Bacterial skin and soft tissue infections in adults: a review of their epidemiology pathogenesis, diagnosis treatment and site of care. Can J Infect Dis Med Microbiol 2008;19(2):173-84
   PubMed Web of Science ®Google Scholar
• Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 2014;59(2):e10-52
   PubMed Web of Science ®Google Scholar
• Vibativ^®, package insert. Theravance; South San Francisco, CA, USA: 2014
   Google Scholar
• Dalvance^®, package insert. Durata Therapeutics; Chicago, IL, USA: 2014
   Google Scholar
• Single dose vs. two dose regimen of dalbavancin for the treatment of acute bacterial skin and skin structure infection. Available from: http://clinicaltrials.gov/show/NCT02127970 [Last accessed 25 November 2014]
   Google Scholar
• Orbactiv^®, package insert. The Medicines Co; Parsippany, NJ, USA: 2014
   Google Scholar
• Allen NE. From vancomycin to oritavancin: the discovery and development of a novel lipoglycopeptide antibiotic. Antinfect Agents Med Chem 2010;9:23-47
   Google Scholar
• Zhanel GG, Schweizer F, Karlowsky JA. Oritavancin: mechanism of action. Clin Infect Dis 2012;54(S3):S214-19
   PubMedGoogle Scholar
• Arhin FF, Sarmiento I, Parr TRJr, Moeck G. Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin. J Antimicrob Chemother 2009;64(4):868-70
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Calic D, Schweizer F, et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs 2010;70:859-86
   PubMed Web of Science ®Google Scholar
• Bhavnani SM, Owen JS, Loutit JS, et al. Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects. Diagn Microbiol Infect Dis 2004;50(2):95-102
   PubMed Web of Science ®Google Scholar
• Fettely GJ, Ong CM, Bhavnani SM, et al. Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800 mg dose. Antimicrob Agents Chemother 2005;49(1):148-52
   PubMed Web of Science ®Google Scholar
• Rubino CM, Van Wart AS, Bhavnani SM, et al. Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia. Antimicrob Agents Chemother 2009;53(10):4422-8
   PubMed Web of Science ®Google Scholar
• Kumar A, Mann HJ, Keshtgarpour M, et al. In vitro characterization of oritavancin clearance from human blood by low-flux, high flux, and continuous renal replacement therapy dialyzers. Int J Artif Organs 2011;34(11):1067-74
   PubMed Web of Science ®Google Scholar
• McKay GA, Beaulieu S, Arhin FF, et al. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. J Antimicrob Chemother 2009;63(6):1191-9
   PubMed Web of Science ®Google Scholar
• Oritavancin (ORI) pharmacokinetic-pharmacodynamic (PK-PD) Analyses for efficacy based on data from patients with acute bacterial skin and skin structure infection. Available from: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=3529&sKey=fe4e0b6d-28c3-4163-a845-4fa1fb1a1637&cKey=d2725e16-04b1-4127-b15d-56153e26b5cb&mKey=5d6b1802-e453-486b-bcbb-b11d1182d8bb [Last accessed 25 November 2014]
   Google Scholar
• Arhin FF, Draghi DC, Pillar CM, et al. Comparative in vitro activity of oritavancin against recent Gram-positive clinical isolates. Antimicrob Agents Chemother 2009;53(11):4762-71
   PubMed Web of Science ®Google Scholar
• Mendes RE, Farrell DJ, Sader HS, Jones RN. Oritavancin microbiologic features and activity results from the surveillance program in the United States. Clin Infect Dis 2012;54(S3):S203-13
   PubMedGoogle Scholar
• Chambers HF. Pharmacology and the treatment of complicated skin and skin structure infections. N Engl J Med 2014;370(23):2238-9
   PubMed Web of Science ®Google Scholar
• Arhin FF, Sarmiento I, Belley A, et al. Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing. Antimicrob Agents Chemother 2008;52(5):1597-603
   PubMed Web of Science ®Google Scholar
• Briefing document for the anti-infective drug advisory committee. Novocid® (oritavancin diphosphate for injection) for treatment of complicated skin and skin structure infections. Available from: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4394b2-04-Targanta.pdf [Last accessed 25 November 2014]
   Google Scholar
• Food and Drug Administration. NDA 206-334 deputy division director summary memo. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206334Orig1s000SumR.pdf [Last accessed 25 November 2014]
   Google Scholar
• Dunbar LM, Milata J, McClure T, et al. Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial. Antimicrob Agents Chemother 2011;55(7):3476-84
   PubMed Web of Science ®Google Scholar
• Corey GR, Kalber H, Mehra P, et al. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med 2014;370(23):2180-90
   PubMed Web of Science ®Google Scholar
• Corey GR, Good S, Jiang H, et al. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Clin Infect Dis 2015;60(2):254-62
   PubMed Web of Science ®Google Scholar
• A study for patients with complicated skin and skin structure infections (SIMPLIFI). Available from: http://clinicaltrials.gov/ct2/show/record/NCT00514527 [Last accessed 25 November 2014]
   Google Scholar
• Open label study evaluating the effects of a single oritavancin infusion on cytochrome P450 in healthy volunteers (DDI). Available from: http://clinicaltrials.gov/show/NCT01784536 [Last accessed 23 October 2014]
   Google Scholar
• FDA approves Orbactiv to treat skin infections. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm408475.htm [Last accessed 10 November 2014]
   Google Scholar
• FDA approves The Medicines Company’s Orbactiv (oritavancin) for use in acute bacterial skin and skin structure infections. Available from: http://ir.themedicinescompany.com/phoenix.zhtml?c=122204&p=irol-newsArticle&ID=1956234 [Last accessed 10 November 2014]
   Google Scholar
• Open-label, dose-finding, pharmacokinetics, safety and tolerability study of oritavancin in pediatric patients with suspected or confirmed bacterial infections. Available from: http://clinicaltrials.gov/ct2/show/NCT02134301?term=oritavancin&rank=5 [Last accessed 29 November 2014]
   Google Scholar